Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Your confirmation email is on its way. Please check your inbox for further instructions.

Viking Therapeutics (VKTX) Earnings Date, Estimates & Call Transcripts

Viking Therapeutics logo
$55.06 -5.54 (-9.14%)
(As of 11/13/2024 ET)

Viking Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 5Estimated
Actual EPS
(Oct. 23)
-$0.22 Beat By $0.02
Consensus EPS
(Oct. 23)
-$0.24

Viking Therapeutics released Q3 2024 earnings on October 23, 2024, reporting an EPS of -$0.22, which topped analysts' consensus estimates of -$0.24 by $0.02. With a trailing EPS of -$0.93, Viking Therapeutics' earnings are expected to decrease next year, from ($0.98) to ($1.44) per share.

VKTX Upcoming Earnings

Viking Therapeutics' next earnings date is estimated for Wednesday, February 5, 2025, based off prior year's reporting schedules.


Skip Charts & View Estimated and Actual Earnings Data

VKTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VKTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Viking Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243-$0.27-$0.25-$0.26
Q2 20243-$0.28-$0.17-$0.24
Q3 20243-$0.29-$0.23-$0.26
Q4 20243-$0.27-$0.24-$0.25
FY 202412-$1.11-$0.89-$1.02
Q1 20251-$0.28-$0.28-$0.28
Q2 20251-$0.28-$0.28-$0.28
Q3 20251-$0.30-$0.30-$0.30
Q4 20251-$0.29-$0.29-$0.29
FY 20254($1.15)($1.15)($1.15)

Viking Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/5/2025
(Estimated)
------- 
10/23/2024Q3 2024-$0.24-$0.22+$0.02-$0.22--    
7/24/2024Q2 2024-$0.26-$0.20+$0.06-$0.20--      
4/24/2024Q1 2024-$0.27-$0.26+$0.01-$0.26--      
2/7/2024Q4 2023-$0.25-$0.25--$0.25--      
10/25/2023Q3 2023-$0.22-$0.23 -$0.01-$0.23--      
7/26/2023Q2 2023-$0.21-$0.19+$0.02-$0.19--      
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

4/26/2023Q1 2023-$0.24-$0.25 -$0.01-$0.25--  
2/8/2023Q4 2022-$0.23-$0.26 -$0.03-$0.26--  

Viking Therapeutics Earnings - Frequently Asked Questions

Viking Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based off last year's report dates. Learn more on VKTX's earnings history.

In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) reported ($0.22) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.24) by $0.02. Learn more on analysts' earnings estimate vs. VKTX's actual earnings.

The conference call for Viking Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Viking Therapeutics's latest earnings report can be read online.
Read Transcript

Viking Therapeutics (NASDAQ:VKTX) has a recorded net income of -$85.89 million. VKTX has generated -$0.93 earnings per share over the last four quarters.

Viking Therapeutics's earnings are expected to decrease from ($0.98) per share to ($1.44) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:VKTX) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners